Our studies provide evidence for the critical role of CPAP in inflammation-mediated hepatocarcinogenesis, and CPAP-mediated upregulation of CCL-16 can be a serum biomarker for early diagnosis of premalignant lesions of HCC. The gene discussed is CPAP; the disease is hepatocellular carcinoma.